

«HEIDELBERG HEALTH ECONOMICS SUMMER SCHOOL»
2024

NOBIS Bruneck, South Tyrol / Italy
September 23-27, 2024

Program Highlights

Faculty

Prof. Amanda Adler (Oxford & London); Dr. Richard Baird (Cambridge, UK); Dr. Meindert Boysen (London, UK); Dr. Cinzia Brunelli (Milan); Prof. Sören Holm (Manchester & Oslo); Dr. Mohit Jain (San Rafael, CA); Christoph Glaetzer (New Brunswick, NJ); Dr. Kevin Haninger (Washington, DC); Dr. Ansgar Hebborn (Basel); Dr. Gergő Merész (Budapest); Prof. Daniel Ollendorf (Boston, MA); Prof. Maarten Postma (Groningen); Prof. Gérard de Pouvourville (Paris); Prof. Jeffrey Richardson (Melbourne, Vic); Prof. Michael Schlander (Heidelberg & Wiesbaden¹); Prof. Wendelin Schramm (Heilbronn²); Dr. Cees Smit (Amsterdam); Dr. Oriol Sola-Morales (Barcelona); Prof. Richard Sullivan (London)

¹Scientific Program Chair: *invited*

updated April 23, 2024 – *may be subject to change & revision without notice*



University of Heidelberg

Key Features

INTENSE HIGH-LEVEL PROGRAM

- ↪ Core Module – one week
- ↪ Introductory Module – optional two-day refresher course

STRONG INTERNATIONAL FACULTY

ADDRESSING EVALUATION ISSUES CAUSED BY

- ↪ precision medicine
- ↪ rare and ultra-rare diseases
- ↪ cell and gene therapies
- ↪ innovative cancer combination treatments
- ↪ advanced therapy medicinal products

DISCUSSING STRENGTHS AND WEAKNESSES OF THE CONVENTIONAL EVALUATION MODEL

EXPLORING WAYS FORWARD TO BETTER INTEGRATE

- ↪ the patients' perspective
and
- ↪ the citizens' perspective

in Health Technology Assessments (HTAs)

ADDRESSING THE MISSING LINKS BETWEEN

- ↪ legal and institutional context
and
- ↪ social norms and preferences

and how to overcome them

PROVIDING UNIQUE NETWORKING OPPORTUNITIES
with thought-leaders in health economics and HTA

Overview

Introductory Module		Core Module				
Friday Sept. 20	Saturday Sept. 21	Monday Sept. 23	Tuesday Sept. 24	Wednesday Sept. 25	Thursday Sept. 26	Friday Sept. 27
	<p>Cost Effectiveness Analysis (II)</p> <p>Modelling Exercises</p>	<p>Health Care Systems & Financing</p> <p>Current Debates</p>	<p>Clinical Effectiveness & Precision Medicine, OMPs, ATMPs</p>	<p>HTA</p> <p>Unresolved Normative & Empirical Issues</p>	<p>Economics</p> <p>Alternatives to the Conventional Paradigm</p>	<p>HTA</p> <p>as Multi-Criteria Decision Analysis?</p>
[Option for Late Arrival]						
<p>Cost Effectiveness Analysis (I)</p> <p>Valuation Costing Exercises</p>	<p>Decision Analysis</p>	<p>Economic Welfare Theory & The Logic of Cost Effectiveness</p> <p>Current Challenges</p>	<p>HTA</p> <p>Cost Effectiveness & Precision Medicine, OMPs, ATMPs</p>	<p>HTA & Setting Limits</p> <p>Industrial Perspectives</p> <p>Citizens' Perspectives</p>	<p>HTAs</p> <p>Patients' Perspectives</p> <p>Socioeconomic Impact Analysis</p>	<p>Perspectives</p>

Economic Evaluation & Health Technology Assessment (HTA)

The relevance of Health Technology Assessments (HTAs) for market access, pricing and reimbursement of health technologies has increased continuously over the last decades. Conventional HTAs predominantly rest on two pillars:

- ▭ an evaluation of clinical effectiveness drawing on well-established principles of evidence-based medicine (EBM),
and
- ▭ an attempt to determine the «value for money» offered by interventions using (some sort of) economic assessment.

Yet the approaches adopted by HTA agencies to assess «value for money» vary greatly. This variance can hardly surprise as issues related to access to health care represent an area permeated with ideologically charged controversy.

The «**Heidelberg Health Economics Summer School**» was inaugurated by the not-for-profit *Institute for Innovation & Valuation in Health Care* (InnoVal^{HC}) in 2006 to contribute to closing gaps between the theory and the practice of Health Technology Assessments (HTAs), with or without formal economic evaluation.

A traditional focus has been the systematic appraisal of strengths, weaknesses, limitations, and – on this basis – the appropriate use of economic evaluation methods, ranging from cost benefit analysis (CBA) and cost utility / cost effectiveness analysis (CUA/CEA) to more recently advocated social cost value analysis (SCVA) and variants. Country-specific HTA case studies are used to discuss the policy relevance of these concepts, addressing examples such as the case of orphan medicinal products (OMPs), advanced therapy medicinal products (ATMPs), the evaluation of medical devices and diagnostics, and personalized medicine.

The **Health Economics Summer School 2024** has been designed to offer a high-level forum for health care decision makers, health economists, clinician scientists, and advanced PhD students (from academia, independent research institutes, and from the research-based biopharmaceutical industry), to discuss the appropriate role, current use, and limitations of economic evaluations to inform Health Technology Assessments, with a view towards future improvement.

The Summer School will be of particular interest and relevance for specialists in the fields of market access, pricing, reimbursement, clinical research and development, and early value assessment.

Highlights

- ↪ Addressing the most important recent developments in the worlds of Health Technology Assessment and health economic evaluation;
- ↪ Practice-orientated with strong theoretical grounding, combining international policy-relevance with a state-of-the art high-level scientific program;
- ↪ Experienced faculty comprised of internationally respected thought leaders in their fields (research & development; Health Technology Assessment; market access, pricing and reimbursement; health economics; industrial economics; medical ethics);
- ↪ Limited number of participants (30 plus faculty and presenters), offering numerous opportunities for interaction with faculty and case studies and group exercises.

Core Module: An Intense One-Week Program

Program highlights and topics addressed include the following, which will be illuminated from an economic and social science perspective:

(a) Monday, September 23, 2024

The Economics of Health Care Financing

- ↪ International health care systems: how do they compare to each other?
- ↪ International health care financing challenges and spending trends
- ↪ Health care resource allocation – who should decide?
- ↪ Agency problems and cost-sharing policies in theory and practice

In case of late arrival, it will be possible to join the Summer School for the afternoon session without losing flow and context. See also => «Application, Registration, Logistics & Support»

Health Economic Cost Value Analyses

- ↪ Cost benefit analysis as the theoretical high ground: «*the only game in town*»?
- ↪ Cost effectiveness analysis – the widely adopted alternative in the context of HTAs
- ↪ Challenges posed by the evaluation of orphan medicinal products (OMPs), advanced therapy medicinal products (ATMPs), medical devices, diagnostics, and «precision medicine»

(b) Tuesday, September 24, 2024

Pharmaceuticals, ATMPs, OMPs, Companion Diagnostics, Medical Devices

(i) Clinical Effectiveness & Cost Effectiveness

- ↪ Precision medicine, companion diagnostics, and new study designs
- ↪ The missing link between novel research & development strategies and HTA principles
- ↪ What are the lessons from the evaluation of OMPs, if any?

(ii) International Approaches and Experience

- ↪ England and Wales
- ↪ France
- ↪ Germany
- ↪ Hungary
- ↪ The Netherlands
- ↪ Spain
- ↪ European Union
- ↪ United States

(iii) Technical Issues in Cost Effectiveness Analysis

- ↪ Health-related quality of life (HRQoL)
- ↪ Different ways to measure HRQoL – how do they compare?
- ↪ «Utility» and its measurement

An evening at Bruneck Castle



Visit of the Bruneck Castle and the «RIPA» Messner Mountain Museum, with its permanent exhibition devoted to the mountain peoples of this world.

Our guide is Christian Tschurtschenthaler, mayor of the City of Bruneck, 2000 – 2013.

The guided tour will be embedded in a Summer School evening reception at the Castle.

(c) Wednesday, September 25, 2024

The Logic of Cost Effectiveness – Revisited

- What are the objectives of collectively financed health schemes?
- In search of «efficiency»
- Institutional and legal context
- Social norms and preferences

Contextual Considerations

- Understanding industrial economics
- What does it cost to develop a new technology?
- The need to set limits – how can we approach «fair» pricing and reimbursement?

The Social Dimension of Health and Health Care

- «Equity» as an objective:
what should be our primary concern – allocative efficiency or distributive justice?
- The case of OMPs: should we value «rarity»?
- Adopting a citizens' perspective
and «social cost value analysis» (SCVA)

(d) Thursday, September 26, 2024



The scientific program on Thursday will take place at the LUMEN Museum of Mountain Photography, located on the summit plateau of the Kronplatz (2,275m above sea level).

The Search for an Alternative Evaluation Paradigm

- ▭ Do we need alternatives to the conventional «logic of cost effectiveness»?
- ▭ Generalized risk-adjusted cost effectiveness analysis («GRACE»)?
- ▭ Social cost value analysis («SCVA»)?
- ▭ Multi-criteria decision analysis («MCDA»)?

Lunch at the AlpINN restaurant will be followed by a guided tour – either to the LUMEN Museum of Mountain Photography, or to the Messner Mountain Museum MMM Corones on the summit plateau of the Kronplatz – a fascinating building created by Zaha Hadid, offering spectacular views from the Lienz dolomites in the east to the Ortler in the west.



What about the Perspective of Patients?

- ▭ The role of patient preferences in economic evaluation
- ▭ What should be the role of patient-reported outcomes (PROs) in HTA?
- ▭ Is there a place for broader socioeconomic impact of impaired health and health care?
- ▭ How might we better integrate the perspective of patients in cost value analysis?

Roundtable Discussion: How Viable is the Search for Alternatives?

(e) Friday, September 27, 2024

Health Technology Assessment and Cost Value Analysis

- ↪ HTA as multi-criteria decision-making by definition
- ↪ Multi-stakeholder involvement: «SwissHTA» as a case study
- ↪ Involvement of patients in decision-making – revisited
- ↪ Due process – evidence-informed deliberation or a black box?

Summing Up

- ↪ Which way forward?
- ↪ Key challenges – revisited
- ↪ What have we learnt?

Introductory Module: An Optional Two-Day Refresher

(f) Friday / Saturday, September 20/21, 2024

For Summer School attendants with little experience or with a little rusty knowledge of health economic evaluation methods, we offer an Introductory Module, which can be booked separately and independently from the Core Program.

Topics Covered

- ↪ Basics principles of decision analysis
- ↪ Valuation principles in economics
- ↪ Health-adjusted life years
- ↪ Costing in theory and practice
- ↪ Applied cost effectiveness analysis
- ↪ Budget impact analysis
- ↪ Good modeling practice
- ↪ Dealing with uncertainty and sensitivity analyses
- ↪ Exercises and group work

Time Schedule

The core program is scheduled to run on Monday from 9:00am to 6:00pm (with an option to join at 2:00pm in case of late arrival); Tuesday 9:00am to 5:30pm; Wednesday 9:00am to 6:00pm, Thursday 9:00am to 7:00pm, Friday 9:00am to 3:00pm. Introductory module, Friday 2:00pm to 7:00pm and Saturday 9:00am to 2:00pm.

Recommended Reading Materials

- Peter J. Neumann et al. (eds.): *Cost-Effectiveness in Health and Medicine (Second Edition)*. Oxford University Press 2017;
- Marthe Gold et al.: *Cost-Effectiveness in Health and Medicine*. Oxford University Press 1996;
- Michael Drummond et al.: *Methods for the Economic Evaluation of Health Care Programs*. Oxford University Press 2015 (4th edition);
- John Brazier et al.: *Measuring and Valuing Health Benefits for Economic Evaluation*. Oxford University Press 2017 (2nd edition);
- Sherry Glied and Peter C. Smith (eds.): *The Oxford Handbook of Health Economics*. Oxford University Press 2011;
- Morris L. Barer, Thomas E. Getzen, and Greg L. Stoddart (eds.): *Health, Health Care and Health Economics – Perspectives on Distribution*. John Wiley & Sons 1998;
- Erik Nord: *Cost-Value Analysis in Health Care. Making Sense out of QALYs*. Cambridge University Press 1999;
- Gavin Mooney: *Challenging Health Economics*. Oxford University Press 2009;
- Thomas Rice: *The Economics of Health Reconsidered*. Health Administration Press 2002 (2nd edn.);
- Daniel M. Hausman and Michael S. McPherson: *Economic Analysis, Moral Philosophy, and Public Philosophy*. Cambridge University Press 2006 (2nd edition);
- Glenn Cohen, Norman Daniels, and Nir Eyal: *Identified versus Statistical Lives. An Interdisciplinary Perspective*. Oxford University Press 2015.

Booking & Logistics

Please see => «*Application, Registration, Logistics & Support*»

For **further information regarding the scientific Summer School program**, please contact Dr. Ramon Schäfer or Professor Michael Schlander at the Institute for Innovation & Valuation in Health Care, An der Ringkirche 4, D-65197 Wiesbaden: michael.schlander@innoval-hc.com and ramon.schaefer@innoval-hc.com, respectively.

Unique Features

Interactive. Unique ratio of 2:1 between registered participants and faculty, allowing for interaction facilitated by workshops sessions, exercises, case studies, and roundtable debates

International. Health care policy makers around the world share many fundamental challenges with regard to financing, reimbursement, pricing and access issues, and the appropriate role of Health Technology Assessments (HTAs) including economic evaluation; accordingly, faculty and participants will be from the Americas, Australia, and Europe

Intense. Make no mistake w.r.t. the unparalleled intensity of the scientific program because of the scenic mountain environment and one day on top of the Kronplatz summit; however, we know that some faculty members and some participants plan to have their spouses accompanying them or to add a few days of private vacation once in South Tyrol

In-depth. Key topics (such as handling of OMPs, ATMPs, cancer combination treatments, medical devices, diagnostics and “precision medicine”) will be addressed from more than one perspective, bringing together experts from a variety of relevant backgrounds (including medical ethics, economics, clinical medicine, academia, HTA, and policy makers)

Impartial. The program will be strictly evidence-based and informed by the latest progress in health economics; a clear line will be drawn between facts and opinions, and there will be room for debate and critical review of popular arguments frequently brought forward in debates

Information. The Heidelberg Health Economics Summer Schools were inaugurated by our Institute in 2006; for a review and evaluation of the highly acclaimed programs, see [here](#). For further information, please feel free to contact us by [e mail](#)

Interested? The program will be most suitable for executives in senior commercial functions (CEOs and Business Unit Directors), market access, and health policy-makers concerned with HTAs and economic evaluation; it may also be of interest to advanced scholars in the field who wish to actively participate in shaping the future development of the regulatory environment w.r.t. patient access, financing, pricing, and reimbursement policies in the health care sector

To apply for registration, please follow this [link](#). An Early Bird discount will be available until April 30, 2024, which will be equivalent to a waiver for the conference package

For a comprehensive 52-page report on prior our **Heidelberg Health Economic Summer Schools** – including an international **evaluation** of the most recent program in 2023 – please follow the link => [here](#).

INNOVAL^{HC}
Institute for Innovation & Valuation
in Health Care



University of Heidelberg

www.innoval-hc.com